{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:49:47Z","timestamp":1782478187355,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012601","name":"South China Agricultural University","doi-asserted-by":"publisher","award":["ZLXD2017003"],"award-info":[{"award-number":["ZLXD2017003"]}],"id":[{"id":"10.13039\/501100012601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007914","name":"University of Texas Southwestern Medical Center","doi-asserted-by":"publisher","award":["2015-RCYJ0002"],"award-info":[{"award-number":["2015-RCYJ0002"]}],"id":[{"id":"10.13039\/100007914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bcp.2019.113716","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:11:55Z","timestamp":1574104315000},"page":"113716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1"],"prefix":"10.1016","volume":"171","author":[{"given":"Chengxiang","family":"Lian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shousong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-636X","authenticated-orcid":false,"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10151","key":"10.1016\/j.bcp.2019.113716_b0005","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.113716_b0010","article-title":"Novel therapies for unresectable and metastatic melanoma","volume":"359","author":"Karimkhani","year":"2017","journal-title":"BMJ"},{"issue":"9839","key":"10.1016\/j.bcp.2019.113716_b0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bcp.2019.113716_b0020","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2019.113716_b0025","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.3390\/cancers10060157","article-title":"Reversal of resistance in targeted therapy of metastatic melanoma: lessons learned from vemurafenib (BRAFV600E-Specific Inhibitor)","volume":"10","author":"Torrescollado","year":"2018","journal-title":"Cancers"},{"issue":"7287","key":"10.1016\/j.bcp.2019.113716_b0030","first-page":"341","article-title":"Naevus lightening in melanoma patients under BRAF\/MEK inhibitor combination therapy versus checkpoint immunotherapy: a histologic and immunohistochemistry analysis","volume":"31","author":"Zhao","year":"2017","journal-title":"Pigment Cell Melanoma Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"12","key":"10.1016\/j.bcp.2019.113716_b0040","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials","volume":"4","author":"Eigentler","year":"2003","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2019.113716_b0045","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaad.2003.12.016","article-title":"Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma","volume":"50","author":"Treudler","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"issue":"16","key":"10.1016\/j.bcp.2019.113716_b0050","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"GAPlant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata","volume":"88","author":"Wall","year":"1966","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.bcp.2019.113716_b0055","first-page":"941","article-title":"The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects","volume":"24","author":"Zhou","year":"2010","journal-title":"Oncol. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2019.113716_b0060","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2019.113716_b0065","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/1759-7714.12884","article-title":"Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis","volume":"9","author":"Imai","year":"2018","journal-title":"Thorac. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2019.113716_b0070","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/annonc\/mdx816","article-title":"S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial","volume":"29","author":"Yamada","year":"2018","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.bcp.2019.113716_b0075","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"9229","key":"10.1016\/j.bcp.2019.113716_b0080","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(00)02586-1","article-title":"Effect of thalidomide on gastrointestinal toxic effects of irinotecan","volume":"356","author":"Govindarajan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2019.113716_b0085","unstructured":"Y. Li, H. Wang, Y. Zhu, Z. Wang, H. Zhang, R. Zhao, et al., Compound of camptothecin and preparation and use thereof, 2016;Patent No. US 9,458,170 B2."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-018-0897-x","article-title":"Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels","volume":"37","author":"Liu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2019.113716_b0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/1566524015666150630125734","article-title":"TNFR1 regulates ovarian cancer cell tumorigenicity through PIK3CB-p110Beta","volume":"15","author":"Peng","year":"2015","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.bcp.2019.113716_b0100","doi-asserted-by":"crossref","first-page":"44172","DOI":"10.1038\/srep44172","article-title":"Epidermal CD147 expression plays a key role in IL-22-induced psoriatic dermatitis","volume":"7","author":"Peng","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2013.07.019","article-title":"A novel interaction between calcium-modulating cyclophilin ligand and Basigin regulates calcium signaling and matrix metalloproteinase activities in human melanoma cells","volume":"339","author":"Tingting","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/leu.2010.225","article-title":"HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells","volume":"25","author":"Liu","year":"2011","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2019.113716_b0115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41389-018-0030-1","article-title":"TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147\/EGFR","volume":"7","author":"Zhang","year":"2018","journal-title":"Oncogenesis"},{"issue":"2","key":"10.1016\/j.bcp.2019.113716_b0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"},{"key":"10.1016\/j.bcp.2019.113716_b0125","doi-asserted-by":"crossref","first-page":"42672","DOI":"10.1038\/srep42672","article-title":"Possible Involvement of F1F0-ATP synthase and Intracellular ATP in Keratinocyte Differentiation in normal skin and skin lesions","volume":"7","author":"Xiaoyun","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0130","doi-asserted-by":"crossref","first-page":"15208","DOI":"10.1038\/s41598-017-15207-w","article-title":"Inhibition of Phosphatidylinositol 3-kinease suppresses formation and progression of experimental abdominal aortic aneurysms","volume":"7","author":"Yu","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2019.113716_b0135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.pan.2018.02.006","article-title":"Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 \/ NF-kB and L1CAM activities","volume":"18","author":"Zuo","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.bcp.2019.113716_b0140","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fbioe.2019.00226","article-title":"IHC Color Histograms for Unsupervised Ki67 Proliferation Index Calculation","volume":"7","author":"Geread","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"11","key":"10.1016\/j.bcp.2019.113716_b0145","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1074\/jbc.M106372200","article-title":"Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides","volume":"277","author":"Marchand","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod. Pathol."},{"issue":"8","key":"10.1016\/j.bcp.2019.113716_b0155","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/acm.2006.12.763","article-title":"Traditional Chinese medicine for the treatment of chronic prostatitis in China: a systematic review and meta-analysis","volume":"12","author":"Chen","year":"2006","journal-title":"J. Altern. Complement. Med."},{"key":"10.1016\/j.bcp.2019.113716_b0160","unstructured":"W. Sun, S. Huang, H. Huang, Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain, 2015; Patent No. US9192602B2."},{"issue":"9","key":"10.1016\/j.bcp.2019.113716_b0165","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1634\/theoncologist.10-9-686","article-title":"Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis","volume":"10","author":"Armstrong","year":"2005","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.bcp.2019.113716_b0170","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/156652412802480899","article-title":"The p53-Bak apoptotic signaling axis plays an essential role in regulating differentiation of the ocular lens","volume":"12","author":"Deng","year":"2012","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ki.2014.226","article-title":"Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury","volume":"87","author":"Peng","year":"2015","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.bcp.2019.113716_b0180","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3724\/SP.J.1206.2011.00368","article-title":"Advance in PUMA and cardiomyocyte apoptosis*","volume":"39","author":"Li","year":"2012","journal-title":"Prog. Biochem. Biophys."},{"issue":"22","key":"10.1016\/j.bcp.2019.113716_b0185","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.4103\/0366-6999.193463","article-title":"I\u03baB kinase mediating the downregulation of p53 and p21 by lipopolysaccharide in human papillomavirus 16+ cervical cancer cells","volume":"129","author":"Tan","year":"2016","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"70","key":"10.1016\/j.bcp.2019.113716_b0190","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0195","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/bmb.20244","article-title":"DNA topology and topoisomerases","volume":"37","author":"Deweese","year":"2018","journal-title":"Biochem. Mol. Biol. Educ."},{"issue":"4","key":"10.1016\/j.bcp.2019.113716_b0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005098","article-title":"Genome-destabilizing effects associated with top1 loss or accumulation of top1 cleavage complexes in yeast","volume":"11","author":"Andersen","year":"2015","journal-title":"PLoS Genet."},{"issue":"5","key":"10.1016\/j.bcp.2019.113716_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156439","article-title":"Topoisomerase 1 regulates gene expression in neurons through cleavage complex-dependent and -independent mechanisms","volume":"11","author":"Mabb","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2019.113716_b0210","doi-asserted-by":"crossref","unstructured":"I. Chourpa, J.F. Riou, Y. Pommier, M. Manfait, Sers and Fluorescence Study of the Molecular Interactions of Camptothecins with DNA and DNA Topoisomerase I and in their Ternary Cleavable Complexes, 1997;5 111-222.","DOI":"10.1007\/978-94-011-5622-6_160"},{"issue":"17","key":"10.1016\/j.bcp.2019.113716_b0215","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1093\/nar\/gkw665","article-title":"Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells","volume":"44","author":"Das","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.113716_b0220","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3390\/biom5031652","article-title":"Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy","volume":"5","author":"Xu","year":"2015","journal-title":"Biomolecules"},{"issue":"24","key":"10.1016\/j.bcp.2019.113716_b0225","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents","volume":"278","author":"Zhan","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2019.113716_b0230","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.molcel.2009.09.007","article-title":"Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase","volume":"35","author":"Cai","year":"2009","journal-title":"Mol. Cell"},{"issue":"16","key":"10.1016\/j.bcp.2019.113716_b0235","doi-asserted-by":"crossref","first-page":"13599","DOI":"10.1074\/jbc.C300060200","article-title":"Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control","volume":"278","author":"Zhenkun","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2019.113716_b0240","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2019.113716_b0245","doi-asserted-by":"crossref","first-page":"170325","DOI":"10.1155\/2012\/170325","article-title":"New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy","volume":"2012","author":"Mirzayans","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"issue":"5","key":"10.1016\/j.bcp.2019.113716_b0250","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bcp.2019.113716_b0255","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/0008-5472.CAN-15-2355","article-title":"p28-Mediated activation of p53 in G2-M phase of the cell cycle enhances the efficacy of DNA damaging and antimitotic chemotherapy","volume":"76","author":"Yamada","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.113716_b0260","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/MCB.18.1.629","article-title":"Effects of p21(Cip1\/Waf1) at both the G1\/S and the G2\/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication","volume":"18","author":"Niculescu","year":"1998","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2019.113716_b0265","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.bcp.2019.113716_b0270","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1039\/C4PY00369A","article-title":"Camptothecin prodrug block copolymer micelles with high drug loading and target specificity","volume":"5","author":"Khan","year":"2014","journal-title":"Polym. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2019.113716_b0275","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/00001813-200209000-00006","article-title":"Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days","volume":"13","author":"Muggia","year":"2002","journal-title":"Anticancer. Drugs"},{"issue":"30","key":"10.1016\/j.bcp.2019.113716_b0280","doi-asserted-by":"crossref","first-page":"21074","DOI":"10.1074\/jbc.M803493200","article-title":"A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes","volume":"283","author":"Lin","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2019.113716_b0285","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1535-7163.MCT-14-0810","article-title":"MGMT expression predicts PARP-mediated resistance to temozolomide","volume":"14","author":"Erice","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bcp.2019.113716_b0290","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.3892\/etm.2017.4998","article-title":"miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican","volume":"14","author":"Yang","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"40","key":"10.1016\/j.bcp.2019.113716_b0295","doi-asserted-by":"crossref","first-page":"25796","DOI":"10.18632\/oncotarget.25376","article-title":"Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells","volume":"9","author":"Wolff","year":"2018","journal-title":"Oncotarget"}],"updated-by":[{"DOI":"10.1016\/j.bcp.2026.118166","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219304150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219304150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:26:06Z","timestamp":1782476766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219304150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":59,"alternative-id":["S0006295219304150"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113716","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.113716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113716"}}